Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Non-alcoholic steatohepatitis (NASH) and resultant liver fibrosis is a major health problem without effective therapy. Some data suggest that galectin-3 null mice are resistant to the development of NASH with fibrosis. We examined the ability of two complex carbohydrate drugs that bind galectin-3, GM-CT-01 and GR-MD-02, to treat NASH with fibrosis in a murine model. GR-MD-02 treatment resulted in marked improvement in liver histology with significant reduction in NASH activity and collagen deposition. Treatments seemed also to improve both glomerulopathy and interstitial fibrosis observed in kidneys. The improvement in liver histology was evident when animals were treated early in disease or after establishment of liver fibrosis. In all measures, GM-CT-01 had an intermediate effect between vehicle and GR-MD-02. Galectin-3 protein expression was increased in NASH with highest expression in macrophages surrounding lipid laden hepatocytes, and reduced following treatment with GR-MD-02, while the number of macrophages was unchanged. Treatment with GR-MD-02 also reduced the expression of pathological indicators including iNOS, an important TH1 inflammatory mediator, CD36, a scavenger receptor for lipoproteins on macrophages, and α-smooth muscle actin, a marker for activated stellate cells which are the primary collagen producing cells in liver fibrosis. We conclude that treatment with these galectin-3 targeting drugs improved histopathological findings of NASH and markedly reduced fibrosis in a murine model of NASH. While the mechanisms require further investigation, the treatment effect is associated with a reduction of galectin-3 expressed by activated macrophages which was associated with regression of NASH, including hepatocellular fat accumulation, hepatocyte ballooning, intra-portal and intra-lobular inflammatory infiltrate, and deposition of collagen. Similar effects were found with GM-CT-01, but with approximately four-fold lower potency than GR-MD-02. The results, in combination with previous experiments in toxin-induced fibrosis, suggest that these galectin-targeting drugs may have potential in human NASH with fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“NAFLD Activity score (NAS) was calculated according to previously described criteria [11,17].”
MethodPathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Ramachandran, P., Pellicoro, A., Vernon, M. A., Boulter, L., Aucott, R. L., Ali, A., Hartland, S. N., Snowdon, V. K., Cappon, A., Gordon-Walker, T. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119964109 · Cited by 1,001 · cited 2×
“Recently, a new subtype of M2macrophages was identified that is critical for resolution of fibrosis in the liver [50].”
BackgroundRegulation of the expression of inducible nitric oxide synthase
Kleinert, H., Pautz, A., Linker, K., & Schwarz, P. M. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.07.030 · Cited by 705
Galectin-3 Expression and Secretion Links Macrophages to the Promotion of Renal Fibrosis
Henderson, N. C., Mackinnon, A. C., Farnworth, S. L., Kipari, T., Haslett, C., Iredale, J. P., Liu, F.-T., Hughes, J., & Sethi, T. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070726 · Cited by 562 · cited 2×
“the preponderance of data from other gal-3 null mouse studies on fibrosis in liver [7], kidney [9,28], lung [8], and heart [29] demonstrates that gal-3 appears to be integral to accumulation of fibrosis in parenchymal tissue.”
BackgroundCritical role of galectin-3 in phagocytosis by macrophages
Sano, H., Hsu, D. K., Apgar, J. R., Yu, L., Sharma, B. B., Kuwabara, I., Izui, S., & Liu, F.-T. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317592 · Cited by 429
N-Glycans in cancer progression
Lau, K. S., & Dennis, J. W. (2008) · Glycobiology · doi:10.1093/glycob/cwn071 · Cited by 390 · cited 1×
“Binding of galectin-3 to Nglycans has been connected to multiple cellular processes including cell adhesion and migration, immune cell function, inflammation, and neoplasia [31,41–45].”
BackgroundFujii, M., Shibazaki, Y., Wakamatsu, K., Honda, Y., Kawauchi, Y., Suzuki, K., Arumugam, S., Watanabe, K., Ichida, T., Asakura, H., et al. (2013) · Medical Molecular Morphology · doi:10.1007/s00795-013-0016-1 · Cited by 355 · cited 14×
“Liver biochemistry To quantify liver hydroxyproline content, a quantitative assessment of collagen content, frozen liver samples (40–70 mg) were processed by an alkaline-acid hydrolysis method [15].”
MethodInfluentialRole of galectin-3 in diabetic nephropathy
Iacobini, C., Amadio, L., Oddi, G., Ricci, C., Barsotti, P., Missori, S., Sorcini, M., Di Mario, U., Pricci, F., & Pugliese, G. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000077402.95720.b4 · Cited by 99
Cited by
Liver Macrophages in Tissue Homeostasis and Disease
Krenkel, O., & Tacke, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.11 · Cited by 1,424
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
“Dose-dependent reduction of NAS, fibrosis and portal pressure in rat and murine models of NASH potentially due to an impact on macrophage polarization and reduced activation of HSCs [349,350].”
BackgroundTargeting hepatic macrophages to treat liver diseases
Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.026 · Cited by 1,003
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Kazankov, K., Jørgensen, S. M. D., Thomsen, K. L., Møller, H. J., Vilstrup, H., George, J., Schuppan, D., & Grønbæk, H. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0082-x · Cited by 941
Johannes, L., Jacob, R., & Leffler, H. (2018) · Journal of Cell Science · doi:10.1242/jcs.208884 · Cited by 618
Ju, C., & Tacke, F. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.104 · Cited by 554
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
Musso, G., Cassader, M., & Gambino, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.3 · Cited by 412
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
Rotman, Y., & Sanyal, A. J. (2017) · Gut · doi:10.1136/gutjnl-2016-312431 · Cited by 410
Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)
Dong, R., Zhang, M., Hu, Q., Zheng, S., Soh, A., Zheng, Y., & Yuan, H. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3311 · Cited by 406
Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z
Sciacchitano, S., Lavra, L., Morgante, A., Ulivieri, A., Magi, F., De Francesco, G., Bellotti, C., Salehi, L., & Ricci, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020379 · Cited by 377
Chalasani, N., Abdelmalek, M. F., Garcia-Tsao, G., Vuppalanchi, R., Alkhouri, N., Rinella, M., Noureddin, M., Pyko, M., Shiffman, M., Sanyal, A., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.296 · Cited by 358
“14 In dietary induced mouse NASH models, belapectin consistently reduced the disease activity, reduced or eliminated fibrosis as measured by liver collagen, and reduced the expression of galectin-3 in liver macrophages.(15) The belapectin treatment of rats with advanced fibrosis and cirrhosis induced by thioacetamide…”
BackgroundSelf-citationGalectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update
Suthahar, N., Meijers, W. C., Silljé, H. H. W., Ho, J. E., Liu, F.-T., & de Boer, R. A. (2018) · Theranostics · doi:10.7150/thno.22196 · Cited by 309
Ibrahim, S. H., Hirsova, P., & Gores, G. J. (2018) · Gut · doi:10.1136/gutjnl-2017-315691 · Cited by 278
The Many Roles of Galectin-3, a Multifaceted Molecule, in Innate Immune Responses against Pathogens
Díaz-Alvarez, L., & Ortega, E. (2017) · Mediators of Inflammation · doi:10.1155/2017/9247574 · Cited by 262
Treatment options for alcoholic and non-alcoholic fatty liver disease: A review
Singh, S., Osna, N. A., & Kharbanda, K. K. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i36.6549 · Cited by 257
Targeting galectin-driven regulatory circuits in cancer and fibrosis
Mariño, K. V., Cagnoni, A. J., Croci, D. O., & Rabinovich, G. A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00636-2 · Cited by 246
Luci, C., Bourinet, M., Leclère, P. S., Anty, R., & Gual, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.597648 · Cited by 195
Alisi, A., Carpino, G., Oliveira, F. L., Panera, N., Nobili, V., & Gaudio, E. (2017) · Mediators of Inflammation · doi:10.1155/2017/8162421 · Cited by 167
“Recent studies highlight that galectin-3 targeting drugs may improve NAFLD-related liver damage, including intraportal and intralobular inflammatory tissue infiltrate, in mouse models [97].”
BackgroundTargeting galectin-3 in inflammatory and fibrotic diseases
Bouffette, S., Botez, I., & De Ceuninck, F. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.06.001 · Cited by 165
The therapeutic potential of galectin-3 inhibition in fibrotic disease
Slack, R. J., Mills, R., & Mackinnon, A. C. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105881 · Cited by 136
Nagasaki, A., Sakamoto, S., Chea, C., Ishida, E., Furusho, H., Fujii, M., Takata, T., & Miyauchi, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-60904-8 · Cited by 82
Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease
Wiering, L., Subramanian, P., & Hammerich, L. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.02.010 · Cited by 80
Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis
Al Attar, A., Antaramian, A., & Noureddin, M. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1894127 · Cited by 47
“Overall, both drugs showed similar effects, but GM-CT-01 had approximately a four-fold lower potency than GM-CT-02 [36].”
InfluentialGalectin-3 in Microglia-Mediated Neuroinflammation: Implications for Central Nervous System Diseases
Tian, Y.-K., Ye, D.-W., Ge, M.-M., Chen, N., Zhou, Y.-Q., & Yang, H. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220201094547 · Cited by 31
Laursen, T. L., Mellemkjær, A., Møller, H. J., Grønbæk, H., & Kazankov, K. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2132145 · Cited by 12
“A galectin-3 inhibitor, GR-MD-02, also known as belapectin, has shown beneficial effects in experimental fibrosis in high-fat-diet fed rats [56] and has been assessed in clinical trials of NASH patients.”
Background
Metadata
- Authors
- Traber, P. G., & Zomer, E.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-12-18
- Volume
- 8
- Issue
- 12
- Pages
- e83481
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1972974730
- Cited by
- 208
- References
- 9
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.